Innoviva, Inc. (INVA) | Investment Case

1. Company Snapshot

1.a. Company Description

Innoviva, Inc.engages in the development and commercialization of pharmaceuticals in the United States and internationally.Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.

Innoviva, Inc.has a strategic partnership with Sarissa Capital Management LP.The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.

The company was formerly known as Theravance, Inc.and changed its name to Innoviva, Inc.in January 2016.

Innoviva, Inc.was incorporated in 1996 and is headquartered in Burlingame, California.

Show Full description

1.b. Last Insights on INVA

Innoviva's recent performance was driven by its strong Q3 earnings, which beat estimates with quarterly earnings of $1.08 per share, compared to $0.02 per share a year ago. The company's infectious diseases and critical care portfolio showed progress, with six presentations at IDWeek 2025. Additionally, its subsidiary, Innoviva Specialty Therapeutics, announced new analyses from the zoliflodacin pivotal Phase 3 trial. The company also entered into a secured credit agreement with Armata Pharmaceuticals for $15 million. Innoviva was added to the Zacks Rank #1 (Strong Buy) List in October.

1.c. Company Highlights

Last Price	20.74
Change Percentage	-0.29%
Open	20.86
Previous Close	20.8
Market Cap ( Millions)	1334
Volume	508252
Year High	22.76
Year Low	16.52
M A 50	19.23
M A 200	19.1

FCF Yield	14.72%
Dividend Yield	0.00%
ROE	5.68%
Debt / Equity	63.08%
Net Debt / EBIDTA	47.86%
Price To Book	1.82
Price Earnings Ratio	33.73
Price To FCF	6.8
Price To sales	3.6
EV / EBITDA	12.44

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Boston Partners Boosts Holdings in Innoviva, Inc. $INVA

Nov -29

Source: defenseworld.net

Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Nov -19

Source: defenseworld.net

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Innoviva, Inc. $INVA

Nov -17

Source: defenseworld.net

Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates

Nov -06

Source: zacks.com

Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength?

Oct -23

Source:

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Oct -21

Source: prnewswire.com

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Oct -20

Source: businesswire.com

New Strong Buy Stocks for October 10th

Oct -10

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.00%)

6. Segments

Respiratory Products

Expected Growth: 8%

Innoviva's Respiratory Products segment growth is driven by increasing adoption of its inhalation therapy products, strong demand for COPD and asthma treatments, and strategic partnerships. Additionally, expanding product portfolio, geographic reach, and growing awareness of respiratory diseases contribute to the 8% growth rate.

7. Detailed Products

Breo Ellipta

A once-daily, inhaled corticosteroid/long-acting beta2-adrenergic agonist (ICS/LABA) combination product for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Anoro Ellipta

A once-daily, inhaled long-acting muscarinic antagonist/long-acting beta2-adrenergic agonist (LAMA/LABA) combination product for the long-term, maintenance treatment of airflow obstruction in patients with COPD.

Trelegy Ellipta

A once-daily, inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta2-adrenergic agonist (ICS/LAMA/LABA) triple-combination product for the long-term, maintenance treatment of airflow obstruction in patients with COPD.

8. Innoviva, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Innoviva, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for chronic obstructive pulmonary disease (COPD) and asthma.

Bargaining Power Of Customers

Innoviva, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the presence of a small number of large pharmacy benefit managers.

Bargaining Power Of Suppliers

Innoviva, Inc. has a moderate bargaining power of suppliers due to the presence of a few large suppliers of raw materials and the company's dependence on these suppliers.

Threat Of New Entrants

Innoviva, Inc. has a high threat of new entrants due to the attractiveness of the respiratory disease market and the presence of several large pharmaceutical companies with the resources to enter the market.

Intensity Of Rivalry

Innoviva, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	39.86%
Debt Cost	4.61%
Equity Weight	60.14%
Equity Cost	6.80%
WACC	5.92%
Leverage	66.29%

11. Quality Control: Innoviva, Inc. passed 6 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Catalyst Pharmaceuticals

A-Score: 5.8/10

Value: 5.4

Growth: 9.8

Quality: 9.4

Yield: 0.0

Momentum: 5.0

Volatility: 5.0

1-Year Total Return ->

Innoviva

A-Score: 4.7/10

Value: 4.9

Growth: 5.4

Quality: 6.6

Yield: 0.0

Momentum: 3.0

Volatility: 8.3

1-Year Total Return ->

Spero Therapeutics

A-Score: 4.5/10

Value: 7.0

Growth: 6.2

Quality: 4.8

Yield: 0.0

Momentum: 9.0

Volatility: 0.0

1-Year Total Return ->

MEI Pharma

A-Score: 4.5/10

Value: 7.6

Growth: 4.8

Quality: 5.2

Yield: 5.0

Momentum: 3.0

Volatility: 1.3

1-Year Total Return ->

Armata Pharmaceuticals

A-Score: 4.4/10

Value: 8.0

Growth: 4.6

Quality: 6.1

Yield: 0.0

Momentum: 8.0

Volatility: 0.0

1-Year Total Return ->

Heron Therapeutics

A-Score: 3.6/10

Value: 7.4

Growth: 6.2

Quality: 5.1

Yield: 0.0

Momentum: 1.0

Volatility: 1.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

-8.47%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

5.92%

Innoviva, Inc. - US45781M1018

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on INVA

1.c. Company Highlights

Better Quality

Less Volatile

Higher Growth

Earnings Beats

Revenues Beats

Earnings Miss

Stable Momentum

Average Growth

Strong Momentum

Fairly Valued

Average Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.00%)

6. Segments

Respiratory Products

Expected Growth: 8%

7. Detailed Products

Breo Ellipta

Anoro Ellipta

Trelegy Ellipta

8. Innoviva, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Innoviva, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

20.74$

Current Price

20.74$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA